Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

The Trump administration has announced the names of 15 drugs targeted for Medicare price negotiations for 2028. The new list of branded medications...

CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks

UnitedHealth Group ($UNH) is set to report its Q4 earnings on January 27. Analysts expect revenue of about $113.77 billion, up 12.9% year‑over‑year...

Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk

Gilead Sciences ( ($GILD) ) has risen by 8.82%. Read on to learn why. Gilead Sciences’ share price climbed 8.82% over the past week, buoyed by a wa...

Why Gilead Sciences Is Suddenly Back in the Spotlight

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insulet (PODD – Research Report) and Gilead Scienc...

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and GRAIL I...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and GRAIL Inc (GRAL)

In a report released today, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $135.00. Breen covers ...

Bernstein Remains a Buy on Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prestige Consumer Healthcare (PBH – Research Report)...

Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Progyny (P...

Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Progyny (PGNY)

Biopharmaceutical company AbbVie ($ABBV) has struck a deal with the Trump administration to invest $100 billion in U.S.-based research and developm...

AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biodesix (BDSX – Research Report), Gilead Sciences...

Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Gilead Sciences (GILD) and Agios Pharma (AGIO)

Analysts are intrested in these 5 stocks: ( ($HAL) ), ( ($SLB) ), ( ($SOFI) ), ( ($PG) ) and ( ($GILD) ). Here is a breakdown of their recent


Halliburton, Schlumberger, SoFi, Procter, Gilead Trending

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and Schrodi...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Schrodinger (SDGR)

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we have ide...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$145.24	+1.64%	3.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$145.24	+1.6%	3.98M
3
4
5
6

GILD

GILD

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel